Department of Infection and Immunity, Research Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Department of Microbiology and Immunology, Alfaisal University School of Medicine, Riyadh, Saudi Arabia.
Front Cell Infect Microbiol. 2018 Oct 22;8:355. doi: 10.3389/fcimb.2018.00355. eCollection 2018.
Viral mutations acquired during the course of chronic hepatitis B virus (HBV) infection are known to be associated with the progression and severity of HBV-related liver disease. This study of HBV-infected Saudi Arabian patients aimed to identify amino acid substitutions within the precore/core (preC/C) region of HBV, and investigate their impact on disease progression toward hepatocellular carcinoma (HCC). Patients were categorized according to the severity of their disease, and were divided into the following groups: inactive HBV carriers, active HBV carriers, liver cirrhosis patients, and HCC patients. Two precore mutations, W28 and G29D, and six core mutations, F24Y, E64D, E77Q, A80I/T/V, L116I, and E180A were significantly associated with the development of cirrhosis and HCC. Six of the seven significant core mutations that were identified in this study were located within immuno-active epitopes; E77Q, A80I/T/V, and L116I were located within B-cell epitopes, and F24Y, E64D, and V91S/T were located within T-cell epitopes. Multivariate risk analysis confirmed that the core mutations A80V and L116I were both independent predictors of HBV-associated liver disease progression. In conclusion, our data show that mutations within the preC/C region, particularly within the immuno-active epitopes, may contribute to the severity of liver disease in patients with chronic hepatitis. Furthermore, we have identified several distinct preC/C mutations within the study population that affect the clinical manifestation and progression of HBV-related disease. The specific identity of HBV mutations that are associated with severe disease varies between different ethnic populations, and so the specific preC/C mutations identified here will be useful for predicting clinical outcomes and identifying the HBV-infected patients within the Saudi population that are at high risk of developing HCC.
已知在慢性乙型肝炎病毒 (HBV) 感染过程中获得的病毒突变与 HBV 相关肝病的进展和严重程度有关。本研究对感染 HBV 的沙特阿拉伯患者进行了研究,旨在鉴定 HBV 前核心/核心 (preC/C) 区的氨基酸取代,并研究其对向肝细胞癌 (HCC) 发展的疾病进展的影响。根据疾病的严重程度对患者进行分类,并分为以下几组:非活动 HBV 携带者、活跃 HBV 携带者、肝硬化患者和 HCC 患者。两个前核心突变 W28 和 G29D 以及六个核心突变 F24Y、E64D、E77Q、A80I/V、L116I 和 E180A 与肝硬化和 HCC 的发生显著相关。本研究中鉴定的七个显著核心突变中有六个位于免疫活性表位内;E77Q、A80I/V 和 L116I 位于 B 细胞表位内,F24Y、E64D 和 V91S/T 位于 T 细胞表位内。多变量风险分析证实,核心突变 A80V 和 L116I 均是 HBV 相关肝病进展的独立预测因子。总之,我们的数据表明,前 C/C 区的突变,特别是免疫活性表位内的突变,可能导致慢性乙型肝炎患者的肝脏疾病严重程度增加。此外,我们在研究人群中鉴定了几个不同的 preC/C 突变,这些突变影响 HBV 相关疾病的临床表现和进展。与严重疾病相关的 HBV 突变的具体特征在不同种族人群中有所不同,因此,这里鉴定的特定 preC/C 突变将有助于预测临床结果并识别沙特人群中发生 HCC 的高风险 HBV 感染患者。